Citigroup Initiates Coverage on Hengrui Pharma with Buy Rating and HK$134 Target

Deep News10:20

Citigroup has issued a research report assigning a Buy rating to Hengrui Pharma (01276) H-shares, with a target price of HK$134. The report highlighted that the company's innovative drug sales for the first quarter of 2026 grew 26% year-on-year to RMB 4.5 billion, increasing their contribution to total product sales from 54% in the same period last year to 62%.

Management has reaffirmed its target of achieving over 30% annual growth in innovative drug sales for 2026, noting that accelerated hospital access in March has laid a foundation for full-year sales growth. In the first quarter of 2026, the company recognized business development revenue of RMB 787 million from its collaboration with GSK, with full-year projections estimated at approximately RMB 250 million.

The progress of collaborative products remains on track. The global Phase III trial for Ribupatide (GLP-1/GIP) was initiated in December 2025, and the global Phase III trial for HRS-1893 (Myosin) is scheduled to commence in 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment